{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:37:48Z","timestamp":1793425068056,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K09517"],"award-info":[{"award-number":["20K09517"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-11319-w","type":"journal-article","created":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T13:34:59Z","timestamp":1752327299000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Trends in the use and efficacy of adjuvant immunotherapy in muscle-invasive urothelial carcinoma"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0026-4079","authenticated-orcid":false,"given":"Shingo","family":"Hatakeyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuya","family":"Kandori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Ikarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Myoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohide","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamitsu","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Oikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Kaiho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisanobu","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiko","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Obara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Habuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikara","family":"Ohyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,12]]},"reference":[{"issue":"1","key":"11319_CR1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.eururo.2020.05.042","volume":"79","author":"M Roupret","year":"2021","unstructured":"Roupret, M. et al. European association of urology guidelines on upper urinary tract urothelial carcinoma: 2020 update. Eur Urol Jan. 79 (1), 62\u201379. https:\/\/doi.org\/10.1016\/j.eururo.2020.05.042 (2021).","journal-title":"Eur Urol Jan"},{"issue":"1","key":"11319_CR2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","volume":"79","author":"JA Witjes","year":"2021","unstructured":"Witjes, J. A. et al. European association of urology guidelines on Muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol Jan. 79 (1), 82\u2013104. https:\/\/doi.org\/10.1016\/j.eururo.2020.03.055 (2021).","journal-title":"Eur Urol Jan"},{"issue":"9","key":"11319_CR3","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/iju.14281","volume":"27","author":"H Matsumoto","year":"2020","unstructured":"Matsumoto, H. et al. Clinical practice guidelines for bladder Cancer 2019 update by the Japanese urological association: summary of the revision. Int J. Urol Sep. 27 (9), 702\u2013709. https:\/\/doi.org\/10.1111\/iju.14281 (2020).","journal-title":"Int J. Urol Sep."},{"issue":"3","key":"11319_CR4","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/iju.15362","volume":"31","author":"K Mori","year":"2024","unstructured":"Mori, K. et al. Summary of the clinical practice guidelines for upper tract urothelial carcinoma 2023 by the Japanese urological association. Int J. Urol Mar. 31 (3), 194\u2013207. https:\/\/doi.org\/10.1111\/iju.15362 (2024).","journal-title":"Int J. Urol Mar."},{"key":"11319_CR5","doi-asserted-by":"publisher","unstructured":"Hara, S. et al. Stage III substaging and outcomes in patients with bladder cancer undergoing radical cystectomy. Int J. Urol Feb. 5 https:\/\/doi.org\/10.1111\/iju.70005 (2025).","DOI":"10.1111\/iju.70005"},{"issue":"9","key":"11319_CR6","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa022148","volume":"28","author":"HB Grossman","year":"2003","unstructured":"Grossman, H. B. et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl. J. Med Aug. 28 (9), 859\u2013866. https:\/\/doi.org\/10.1056\/NEJMoa022148 (2003).","journal-title":"N Engl. J. Med Aug"},{"issue":"6","key":"11319_CR7","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","volume":"21","author":"M Yin","year":"2016","unstructured":"Yin, M. et al. Neoadjuvant chemotherapy for Muscle-Invasive bladder cancer: A systematic review and Two-Step Meta-Analysis. Oncologist Jun. 21 (6), 708\u2013715. https:\/\/doi.org\/10.1634\/theoncologist.2015-0440 (2016).","journal-title":"Oncologist Jun"},{"issue":"10","key":"11319_CR8","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/iju.15524","volume":"31","author":"Y Hattori","year":"2024","unstructured":"Hattori, Y. et al. Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer. Int J. Urol Oct. 31 (10), 1102\u20131106. https:\/\/doi.org\/10.1111\/iju.15524 (2024).","journal-title":"Int J. Urol Oct."},{"issue":"12","key":"11319_CR9","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1111\/iju.15563","volume":"31","author":"S Morizane","year":"2024","unstructured":"Morizane, S. et al. Japanese expert consensus on the standardization of robot-assisted pelvic lymph node dissection in urological surgery: extent of pelvic lymph node and surgical technique. Int J. Urol Dec. 31 (12), 1300\u20131310. https:\/\/doi.org\/10.1111\/iju.15563 (2024).","journal-title":"Int J. Urol Dec."},{"issue":"7","key":"11319_CR10","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/iju.15465","volume":"31","author":"Y Sakura","year":"2024","unstructured":"Sakura, Y. et al. Effectiveness of adjuvant chemotherapy for patients who undergo radical cystectomy without neoadjuvant chemotherapy: A retrospective cohort study of 115 advanced bladder cancer patients with pathological lymph node classification. Int J. Urol Jul. 31 (7), 785\u2013792. https:\/\/doi.org\/10.1111\/iju.15465 (2024).","journal-title":"Int J. Urol Jul"},{"issue":"1","key":"11319_CR11","doi-asserted-by":"publisher","first-page":"102249","DOI":"10.1016\/j.clgc.2024.102249","volume":"23","author":"CV Suartz","year":"2025","unstructured":"Suartz, C. V. et al. Reevaluating the role of extended pelvic lymphadenectomy in Muscle-Invasive bladder cancer: insights from SWOG S1011 and LEA AB 25\u2009\u2013\u200902 trials. Clin Genitourin. Cancer Feb. 23 (1), 102249. https:\/\/doi.org\/10.1016\/j.clgc.2024.102249 (2025).","journal-title":"Clin Genitourin. Cancer Feb"},{"issue":"13","key":"11319_CR12","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJMoa2401497","volume":"3","author":"SP Lerner","year":"2024","unstructured":"Lerner, S. P. et al. Standard or extended lymphadenectomy for muscle-invasive bladder Cancer. N Engl. J. Med Oct. 3 (13), 1206\u20131216. https:\/\/doi.org\/10.1056\/NEJMoa2401497 (2024).","journal-title":"N Engl. J. Med Oct."},{"issue":"2","key":"11319_CR13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/bju.16296","volume":"134","author":"A Matsuda","year":"2024","unstructured":"Matsuda, A. et al. Prognostic impact of histological discordance between transurethral resection and radical cystectomy. BJU Int Aug. 134 (2), 207\u2013218. https:\/\/doi.org\/10.1111\/bju.16296 (2024).","journal-title":"BJU Int Aug"},{"key":"11319_CR14","doi-asserted-by":"publisher","unstructured":"Hatakeyama, S. et al. Effects of the number of neoadjuvant cycles and addition of adjuvant chemotherapy on the prognosis of muscle-invasive bladder cancer treated with radical cystectomy. Cancer Med. 14 (9), e70782. https:\/\/doi.org\/10.1002\/cam4.70782 (May 2025).","DOI":"10.1002\/cam4.70782"},{"issue":"12","key":"11319_CR15","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s10147-024-02636-7","volume":"29","author":"M Kato","year":"2024","unstructured":"Kato, M. et al. Reproductive organ involvement in women undergoing radical cystectomy for urothelial bladder cancer: a nationwide multicenter study. Int J. Clin. Oncol Dec. 29 (12), 1937\u20131945. https:\/\/doi.org\/10.1007\/s10147-024-02636-7 (2024).","journal-title":"Int J. Clin. Oncol Dec."},{"issue":"9","key":"11319_CR16","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1111\/iju.15505","volume":"31","author":"J Miki","year":"2024","unstructured":"Miki, J. et al. Oncological outcomes of prophylactic urethrectomy at the time of radical cystectomy for bladder cancer: A nationwide multi-institutional study. Int J. Urol Sep. 31 (9), 1009\u20131016. https:\/\/doi.org\/10.1111\/iju.15505 (2024).","journal-title":"Int J. Urol Sep."},{"issue":"4","key":"11319_CR17","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/iju.15665","volume":"32","author":"M Shiga","year":"2025","unstructured":"Shiga, M. et al. The correlation between discrepancies in clinical and pathological T stages and overall survival in upper urinary tract urothelial carcinoma: analysis of the hospital-based cancer registry data in Japan. Int J. Urol Apr. 32 (4), 394\u2013400. https:\/\/doi.org\/10.1111\/iju.15665 (2025).","journal-title":"Int J. Urol Apr"},{"issue":"5","key":"11319_CR18","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/iju.70011","volume":"32","author":"F Urabe","year":"2025","unstructured":"Urabe, F. & Yamaguchi, R. Evaluating risk factors for pathological upstaging in upper tract urothelial carcinoma. Int J. Urol May. 32 (5), 608\u2013609. https:\/\/doi.org\/10.1111\/iju.70011 (2025).","journal-title":"Int J. Urol May"},{"issue":"5","key":"11319_CR19","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/iju.15681","volume":"32","author":"H Yamane","year":"2025","unstructured":"Yamane, H. et al. Risk scoring system for evaluating pathological upstaging after radical nephroureterectomy for upper tract urothelial carcinoma: A multicenter study in Japan. Int J. Urol May. 32 (5), 502\u2013507. https:\/\/doi.org\/10.1111\/iju.15681 (2025).","journal-title":"Int J. Urol May"},{"key":"11319_CR20","doi-asserted-by":"publisher","unstructured":"Gavi, F. et al. Assessing trifecta and pentafecta success rates between robot-assisted vs. open radical cystectomy: A propensity score-matched analysis. Cancers (Basel) Mar. 25 (7). https:\/\/doi.org\/10.3390\/cancers16071270 (2024).","DOI":"10.3390\/cancers16071270"},{"key":"11319_CR21","doi-asserted-by":"publisher","unstructured":"Bizzarri, F. P., Nelson, A. W., Colquhoun, A. J. & Lobo, N. Utility of Fluorodeoxyglucose positron emission tomography\/computed tomography in detecting lymph node involvement in comparison to conventional imaging in patients with bladder cancer with variant histology. Eur Urol. Oncol Apr. 17 https:\/\/doi.org\/10.1016\/j.euo.2025.03.019 (2025).","DOI":"10.1016\/j.euo.2025.03.019"},{"issue":"1","key":"11319_CR22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.eururo.2021.09.028","volume":"81","author":"Advanced Bladder Cancer Meta-analysis Collaborators G","year":"2022","unstructured":"Advanced bladder cancer meta-analysis collaborators G. Adjuvant chemotherapy for Muscle-invasive bladder cancer: A systematic review and Meta-analysis of individual participant data from randomised controlled trials. Eur Urol Jan. 81 (1), 50\u201361. https:\/\/doi.org\/10.1016\/j.eururo.2021.09.028 (2022).","journal-title":"Eur Urol Jan"},{"issue":"22","key":"11319_CR23","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"3","author":"DF Bajorin","year":"2021","unstructured":"Bajorin, D. F. et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl. J. Med Jun. 3 (22), 2102\u20132114. https:\/\/doi.org\/10.1056\/NEJMoa2034442 (2021).","journal-title":"N Engl. J. Med Jun"},{"issue":"4","key":"11319_CR24","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","volume":"22","author":"J Bellmunt","year":"2021","unstructured":"Bellmunt, J. et al. Adjuvant Atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 22 (4), 525\u2013537. https:\/\/doi.org\/10.1016\/S1470-2045(21)00004-8 (2021).","journal-title":"Lancet Oncol."},{"key":"11319_CR25","doi-asserted-by":"publisher","first-page":"S1152","DOI":"10.1016\/j.annonc.2024.08.2077","volume":"35","author":"H Ebrahimi","year":"2024","unstructured":"Ebrahimi, H. et al. Real-world (RW) characteristics and outcomes in patients (pts) with muscle-invasive urothelial carcinoma (MIUC) treated with adjuvant nivolumab (NIVO) with or without neoadjuvant chemotherapy (NAC). Annals Oncology Sep. 35, S1152\u2013S1152. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2077 (2024).","journal-title":"Annals Oncology Sep."},{"issue":"13","key":"11319_CR26","doi-asserted-by":"publisher","first-page":"102744","DOI":"10.1016\/j.fjurol.2024.102744","volume":"34","author":"A Guilbert","year":"2024","unstructured":"Guilbert, A. et al. Real-world evaluation of nivolumab utilization in adjuvant treatment of localized muscle-invasive urothelial carcinoma. Fr J. Urol Dec. 34 (13), 102744. https:\/\/doi.org\/10.1016\/j.fjurol.2024.102744 (2024).","journal-title":"Fr J. Urol Dec."},{"issue":"6_suppl","key":"11319_CR27","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1200\/JCO.2021.39.6_suppl.391","volume":"39","author":"DF Bajorin","year":"2021","unstructured":"Bajorin, D. F. et al. First results from the phase 3 checkmate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC). J. Clin. Oncol. 39 (6_suppl), 391\u2013391. https:\/\/doi.org\/10.1200\/JCO.2021.39.6_suppl.391 (2021).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"11319_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa2401726","volume":"2","author":"AB Apolo","year":"2025","unstructured":"Apolo, A. B. et al. Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma. N Engl. J. Med Jan. 2 (1), 45\u201355. https:\/\/doi.org\/10.1056\/NEJMoa2401726 (2025).","journal-title":"N Engl. J. Med Jan"},{"issue":"1","key":"11319_CR29","doi-asserted-by":"publisher","first-page":"102288","DOI":"10.1016\/j.clgc.2024.102288","volume":"23","author":"I Mamede","year":"2025","unstructured":"Mamede, I. et al. Adjuvant immunotherapy in high-risk muscle-invasive urothelial cancer: an updated Meta-Analysis of randomized controlled trials. Clin Genitourin. Cancer Feb. 23 (1), 102288. https:\/\/doi.org\/10.1016\/j.clgc.2024.102288 (2025).","journal-title":"Clin Genitourin. Cancer Feb"},{"issue":"3","key":"11319_CR30","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.urolonc.2024.08.003","volume":"43","author":"L Oscar-Thompson","year":"2025","unstructured":"Oscar-Thompson, L. et al. Adjuvant immunotherapy in high-risk muscle invasive urothelial carcinoma: A systematic review and meta-analysis of randomized clinical trials. Urol Oncol Mar. 43 (3), 156\u2013163. https:\/\/doi.org\/10.1016\/j.urolonc.2024.08.003 (2025).","journal-title":"Urol Oncol Mar."},{"issue":"1","key":"11319_CR31","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1007\/s00345-024-05147-2","volume":"18","author":"RK Sayyid","year":"2024","unstructured":"Sayyid, R. K. et al. Adjuvant immune checkpoint inhibitors for urothelial carcinoma: systematic review and Meta-analysis. World J. Urol. Jul. 18 (1), 418. https:\/\/doi.org\/10.1007\/s00345-024-05147-2 (2024).","journal-title":"World J. Urol Jul"},{"issue":"1","key":"11319_CR32","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/MOU.0000000000001237","volume":"1","author":"RR Bhanvadia","year":"2025","unstructured":"Bhanvadia, R. R., Khene, Z. E. & Margulis, V. Perioperative systemic therapy, current paradigm and ongoing clinical trials in upper tract urothelial cancer. Curr. Opin. Urol. Jan. 1 (1), 83\u201388. https:\/\/doi.org\/10.1097\/MOU.0000000000001237 (2025).","journal-title":"Curr Opin. Urol Jan"},{"issue":"10232","key":"11319_CR33","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","volume":"18","author":"A Birtle","year":"2020","unstructured":"Birtle, A. et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet Apr. 18 (10232), 1268\u20131277. https:\/\/doi.org\/10.1016\/S0140-6736(20)30415-3 (2020).","journal-title":"Lancet Apr"},{"key":"11319_CR34","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/iju.70122","volume":"23","author":"D Sasaki","year":"2025","unstructured":"Sasaki, D. et al. PD-L1 and Ki-67 expression before and after neoadjuvant chemotherapy in Muscle-Invasive bladder Cancer. Int. J. Urol. May. 23, 32. https:\/\/doi.org\/10.1111\/iju.70122 (2025).","journal-title":"Int J. Urol May"},{"issue":"6","key":"11319_CR35","first-page":"393","volume":"43","author":"P Russo","year":"2025","unstructured":"Russo, P. et al. SIRI as a biomarker for bladder neoplasm: utilizing decision curve analysis to evaluate clinical net benefit. Urol. Oncol. Jun. 43 (6), 393. .e1-393.e8 (2025).","journal-title":"Urol Oncol Jun"},{"issue":"4","key":"11319_CR36","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.eururo.2017.12.018","volume":"73","author":"GP Paner","year":"2018","unstructured":"Paner, G. P. et al. Updates in the eighth edition of the Tumor-Node-Metastasis staging classification for urologic cancers. Eur. Urol. Apr.. 73 (4), 560\u2013569. https:\/\/doi.org\/10.1016\/j.eururo.2017.12.018 (2018).","journal-title":"Eur Urol Apr"},{"issue":"6","key":"11319_CR37","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.euf.2018.03.003","volume":"5","author":"M Momota","year":"2019","unstructured":"Momota, M. et al. The impact of preoperative severe renal insufficiency on poor postsurgical oncological prognosis in patients with urothelial carcinoma. Eur. Urol. Focus Nov. 5 (6), 1066\u20131073. https:\/\/doi.org\/10.1016\/j.euf.2018.03.003 (2019).","journal-title":"Eur Urol. Focus Nov"},{"issue":"2","key":"11319_CR38","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41585-020-00404-6","volume":"02","author":"DM Jiang","year":"2021","unstructured":"Jiang, D. M. et al. Defining cisplatin eligibility in patients with muscle-invasive bladder cancer. Nat. Reviews Urol. 02 (2), 104\u2013114. https:\/\/doi.org\/10.1038\/s41585-020-00404-6 (2021). \/01 2021.","journal-title":"Nat. Reviews Urol."},{"issue":"17","key":"11319_CR39","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1200\/jco.2011.34.8433","volume":"10","author":"MD Galsky","year":"2011","unstructured":"Galsky, M. D. et al. Treatment of patients with metastatic urothelial cancer unfit for Cisplatin-based chemotherapy. J Clin. Oncol Jun. 10 (17), 2432\u20132438. https:\/\/doi.org\/10.1200\/jco.2011.34.8433 (2011).","journal-title":"J Clin. Oncol Jun"},{"issue":"9","key":"11319_CR40","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.6004\/jnccn.2018.0072","volume":"16","author":"TW Flaig","year":"2018","unstructured":"Flaig, T. W. et al. NCCN guidelines insights: bladder cancer, version 5.2018. J Natl. Compr. Canc Netw Sep. 16 (9), 1041\u20131053. https:\/\/doi.org\/10.6004\/jnccn.2018.0072 (2018).","journal-title":"J Natl. Compr. Canc Netw Sep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-11319-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-11319-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-11319-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T13:34:59Z","timestamp":1752327299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-11319-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,12]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11319"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-11319-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6194793\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,12]]},"assertion":[{"value":"10 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Shingo Hatakeyama received honoraria from Janssen Pharmaceutical K.K., Astellas Pharma Inc., AstraZeneca K.K., Ono Pharmaceutical Co., Ltd., Bayer AG, Pfizer Inc., Bristol-Myers Squibb, Merck Biopharma Co., Ltd., Kaneka Corporation, and Nipro Corporation. Hiroyuki Nishiyama received honoraria from Astellas, BMS, Janssen, MSD, Ono, and Pfizer, and a grant from Chugai and Astellas. The other authors have no conflicts of interest to declare. Tomonori Habuchi received honoraria from Janssen Pharmaceutical K.K., Nippon Kayaku Co., LTD., Takeda Pharmaceutical Company Ltd., Astellas Pharma Inc., Daiichi Sankyo Company, Ltd., AstraZeneca K.K., Sanofi S.A., Novartis Pharmaceuticals and Bayer AG. Tomonori Habuchi also received research funding supports from Mochida Pharmaceutical Co., Novartis Pharmaceuticals Co, LTD., Pharmaceuticals Co, LTD. and Sysmex Co. Wataru Obara received honoraria from Astellas Pharma Inc., AstraZeneca K.K., Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb, Merck Biopharma Co., Ltd., Takeda Pharmaceutical Company Ltd., Merck Biopharma. Norihiko Tsuchiya received honoraria from Janssen Pharmaceutical K.K., Pfizer Inc., Takeda Pharmaceutical Co. Ltd., Astellas Pharma Inc., Ono Pharmaceuticals Co., Ltd., MSD K.K., Merk & Co., Inc. Other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The need for informed consent to participate was waived by an Institutional Review Board by the ethics committee of the Hirosaki University School of Medicine and all participating hospitals. Written informed consent was not obtained from individual patients due to the use of an opt-out approach.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors approved for the publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"25247"}}